Christini Takemi Emori

Verified @yahoo.com.br

Infectology Department/Faculdade de Medicina da Universidade de São Paulo, USP, São Paulo, Brasil

Christini Takemi Emori


            Download Compact PDF  
https://researchid.co/christini
17

Scopus Publications

163

Scholar Citations

7

Scholar h-index

7

Scholar i10-index

Scopus Publications

  • High detection rate of parasitic load by qPCR targeting 18S rDNA in blood of patients with active leishmaniasis lesions
    Gabriel Victor Castanheira, Valdir Sabbaga Amato, Felipe Francisco Tuon, Letícia Ramos Dantas, Silvio Fernando Guimarães de Carvalho, Thallyta Maria Vieira, Ana Paula Venuto Moura, Jackeline Maria de Sousa Lima Lopes, Gustavo Henrique Johanson, Christini Takemi Emori, Regina Maia de Souza
    European Journal of Clinical Microbiology and Infectious Diseases, 2025
  • Early noninvasive evaluation of liver fibrosis after hepatitis c treatment: the impact of inflammation
    João Batista XAVIER, Joel SCHMILLEVITCH, Christini EMORI, Silvia UEHARA, Eunice Jadriana NUNES, Maria Lucia FERRAZ
    Arquivos De Gastroenterologia, 2024
    Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV). Objective: To evaluate hepatic fibrosis using ARFI technology before and after successive treatments for chronic HCV. Methods: We prospectively included 50 adult patients with chronic HCV (genotype 1). Patients were first submitted to triple therapy with first-generation protease inhibitors (boceprevir and telaprevir) at the hepatitis division of the Gastroenterology Department of the Federal University of São Paulo. The non-responders underwent re-treatment with interferon-free direct-acting antiviral agents (DDAs - sofosbuvir associated with daclatasvir or simeprevir). Assessment of hepatic stiffness by ARFI was performed before and after the first treatment and before and after the re-treatment with DDAs. Results: ARFI values decreased significantly after treatments. In patients on first-generation protease inhibitor therapy and achieving sustained virological response (SVR), ARFI decreased from 2.41±0.58 pre-treatment to 2.02+/-0.58 (P<0.042) post-treatment. In patients who did not reach SVR, that is, non-responders, a significant reduction was similarly observed (2.39±0.63 to 2.03±0.54; P<0.001 before and after treatment, respectively). Before starting the re-treatment, non-responders had elevated ARFI values again, dropping after SVR following re-treatment (from 2.46±0.57 to 1.45±0.68, P<0.004). Laboratory parameters such as AST and ALT were directly correlated to ARFI elastography. Conclusion: The evaluation of hepatic elastography by the ARFI method before and after (6 - 9 months) successive treatment of hepatitis C in responders and non-responders led to the conclusion that the reduction of elastography parameters seems to be related to a decrease in hepatic inflammation rather than a reduction in fibrosis per se.
  • Case Report: Cutaneous Leishmaniasis in a Rheumatoid Arthritis Patient Receiving Methotrexate
    Valdir Sabbaga Amato, Regina Maia de Souza, Lucas Augusto Moyses Franco, Roberta Cristina Ruedas Martins, Camila Alves Maia da Silva, Christini Takemi Emori, Beatriz Julieta Celeste, Gabriel Victor Castanheira, Felipe Francisco Tuon
    American Journal of Tropical Medicine and Hygiene, 2022
    The immunosuppressive effect of methotrexate has rarely been associated with reactivation of cutaneous leishmaniasis. Here we present a case of a cutaneous leishmaniasis patient with atypical clinical symptoms without splenomegaly but with cutaneous manifestations after treatment of rheumatoid arthritis with methotrexate and blood recovery of the parasite. Next-generation sequencing was used to identify Leishmania infantum chagasi in the patient’s blood sample.
  • Hepatitis B Reactivation in HBsAg Negative Renal Transplant Patients with Evidence of Previous HBV Infection: A Not Neglectable Occurrence
    Ana Paula Leopercio, Christini Emori, Elisabete Calore Neiva, Ana Lucia Silva Souza, Ana Cristina Amaral, Gustavo Almeida Vieira, Raimundo Araujo Gama, Jose Osmar Medina-Pestana, Maria Lúcia Ferraz
    Obm Transplantation, 2022
    Hepatitis B virus (HBV) infection is frequent among patients with chronic kidney disease (CKD). HBV reactivation after kidney transplant (KT) is more common in patients with HBsAg+; however, it can also occur in previously infected individuals, particularly those with HBsAg negative and total antiHBc positive (HBsAg-/antiHBcT+). However, reactivation in this population has scarce and conflicting data. This study aimed to assess the reactivation risk in KT recipients with previous HBV infection (antiHBcT+). A retrospective cohort study was conducted, including patients with KT between January 1993 and December 2012 with HBsAg+ (G1) and with previous HBV infection (antiHBcT+) (G2). A total of 10,493 transplants were performed in this period. A total of 203 patients were included (122 HBsAg+ and 81 HBsAg-/anti-HBcT+). The reactivation of infection occurred in 24.6% (30/38) patients and 9.8% (8/30) in G1 and G2, respectively. Detectable HCV RNA, indicating HCV coinfection, was the only variable related to reactivation in patients with antiHBcT+, protecting its occurrence (p: 0.001). In conclusion, reactivation of HBV infection in KT recipients with the previous infection, occurring in approximately 10% of cases, should be considered. Complete HBV serology is recommended before KT, and patients with HBsAg-/anti-HBcT+ should be monitored after the procedure. Prophylaxis may be indicated when adequate follow-up is not feasible. HCV coinfection appears to be a protective factor for reactivation.
  • Observational Study Evaluating the Outcome of Cirrhotic Hepatitis C Patients Submitted to Renal Transplantation
    Christini Takemi Emori, Sílvia Naomi Oliveira Uehara, Ana Cristina Amaral, Roberto José Carvalho-Filho, Sílvia Regina Moreira, Ivonete Sandra de Souza e Silva, Valéria Pereira Lanzoni, Ana Lucia Silva-Souza, Raimundo Araújo Gama, Eunice Jadriana Soares Nunes, Ana Paula Serra Leopércio, Flávia Appel, Sandra Regina de Almeida Carvalho, Antônio Eduardo Benedito Silva, José Osmar Medina-Pestana, Maria Lucia Gomes Ferraz
    Transplantation Proceedings, 2020
  • Changing pattern of chronic hepatitis C in renal transplant patients over 20 years
    Christini T. Emori, Sílvia N.O. Uehara, Roberto J. Carvalho-Filho, Ana Cristina Amaral, Ivonete S. de Souza e Silva, Valéria P. Lanzoni, Sílvia R. Moreira, Ana Lúcia Silva-Souza, Raimundo A. Gama, Eunice J.S. Nunes, Ana Paula.S. Leopércio, Flávia Appel, Antônio Eduardo B. Silva, José O. Medina-Pestana, Maria L.G. Ferraz
    European Journal of Gastroenterology and Hepatology, 2019
    BACKGROUND The prevalence and clinical epidemiological profile of hepatitis C virus (HCV) infection have changed over time. AIM This study aimed to evaluate these changes in renal transplant recipients (RTx) comparing two different decades. MATERIALS AND METHODS RTx with HCV referred to RTx from 1993 to 2003 (A) and from 2004 to 2014 (B) were studied retrospectively. The demographic and clinical characteristics and different outcomes were compared between groups A and B. Variables that were statistically different were tested for inclusion in a multivariate Cox proportional hazard model predicting patient survival within the group. RESULTS Among 11 715 RTx, the prevalence of HCV was 7% in A and 4.9% in B. In the more recent period (B), the mean age was older (46.2 vs. 39.5 years), with more males (72 vs. 60.7%), larger number of deceased donors (74 vs. 55%), higher percentage of previous RTx (27 vs. 13.7%), less frequent history of blood transfusion (81 vs. 89.4%), lower prevalence of hepatitis B virus coinfection (4.7 vs. 21.4%), and higher percentage of cirrhotic patients (13 vs. 5%). Patients of group B more frequently underwent treatment of HCV (29 vs. 9%), less frequently used azathioprine (38.6 vs. 60.7%) and cyclosporine (11.8 vs. 74.7%), and more frequently used tacrolimus (91 vs. 27.3%). In the outcomes, graft loss showed no difference between periods; however, decompensation was more frequent (P=0.007) and patients' survival was lower in the more recent period (P=0.032) compared with the earlier one. CONCLUSION The profile of RTx with HCV has changed over the last 20 years. Despite a decrease in the prevalence of HCV, new clinical challenges have emerged, such as more advanced age and a higher prevalence of cirrhosis.
  • Prevalence of hepatitis delta virus among hemodialysis and renal transplant patients
    Alessandra Maria Mont`Alverne Pierre, Ana Cristina de Castro Amaral Feldner, Roberto José de Carvalho Filho, Edmundo Pessoa de Almeida Lopes, Michele Soares Gomes Gouvea, João Renato Rebello Pinho, Claudia Teresa Carvente, Christini Takemi Emori, Genimari Arruda da Silva, Maria Lúcia Cardoso Gomes Ferraz
    International Journal of Artificial Organs, 2018
    Introduction: Hepatitis B virus infection is an important cause of liver disease in hemodialysis patients and renal transplant recipients. Hepatitis Delta virus is a defective virus transmitted by the same route of hepatitis B virus, which requires the helper function of hepatitis B virus. Data about hepatitis B virus/hepatitis delta virus coinfection are scarce and there are no studies regarding the coinfection among hemodialysis patients and renal transplant in our country. Objective: This study aimed to investigate the prevalence of hepatitis delta virus infection among hemodialysis patients and renal transplant recipients. Methods: Cross-sectional study analyzing virological markers of hepatitis B virus and hepatitis delta virus infection and biochemical and clinical features of liver disease of patients infected with hepatitis B virus in hemodialysis and renal transplant. Results: A total of 117 HBsAg-positive patients (46 hemodialysis and 71 renal transplant) were included. The mean age was 48.5 ± 11.8 years and 67% were males. Antiviral therapy was given to 74% of patients. Liver function tests were within the normal range. HBeAg-positive was found in 35% of patients and median hepatitis B virus DNA was 2.98 log (IU/mL). Cirrhosis was detected in 26.5% of patients. The prevalence of anti–hepatitis delta virus total antibody (+) was 1.7% (2/117). None of the 2 patients had active hepatitis delta virus infection, since all samples tested negative for hepatitis delta virus–RNA. Conclusion: The results suggest a low prevalence rate of coinfection B and D in hemodialysis and renal transplant recipients in this population.
  • Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection
    Rita C.F. Tavares, Ana C.C.A. Feldner, João R.R. Pinho, Silvia N.O. Uehara, Christini T. Emori, Roberto J. Carvalho-Filho, Ivonete S.S. Silva, Rúbia A.F. Santana, Vanessa F.D. de Castro, Gregório T. F. Castoli, Charliana U. Cristovão, Maria L.C.G. Ferraz
    European Journal of Gastroenterology and Hepatology, 2017
    Background NS3 protease inhibitors (PIs) were the first direct antiviral agents used for the treatment of hepatitis C virus. The combination of second-wave PIs with other direct antiviral agents enabled the use of interferon-free regimens for chronic kidney disease patients on dialysis and renal transplant (RTx) recipients, populations in which the use of interferon and ribavirin is limited. However, the occurrence of PI resistance-associated variants (RAVs), both baseline and induced by therapy, has resulted in the failure of many treatment strategies. Methods The aim of this study was to estimate the prevalence of PI RAVs and of the Q80K polymorphism in chronic kidney disease patients on hemodialysis and RTx recipients. Direct sequencing of the NS3 protease was performed in 67 patients (32 hemodialysis and 35 RTx).Results RAVs to PIs were detected in 18% of the patients: V55A (9%), V36L (1.5%), T54S (1.5%), S122N (1.5%), I170L (1.5%), and M175L (1.5%). Only 1.5% of the patients carried the Q80K polymorphism. The frequency of these mutations was more than two times higher in patients infected with GT1a (25%) than GT1b (9.7%) (P=0.1). The mutations were detected in 20% of treatment-naive patients and in 15.6% of peginterferon/ribavirin-experienced patients (P=0.64). Furthermore, no mutation that would confer high resistance to PIs was detected.Conclusion The Q80K polymorphism was rare in the population studied. The occurrence of RAVs was common, with predominance in GT1a. However, the variants observed were those associated with a low level of resistance to PIs, facilitating the use of these drugs in this special group of patients.
  • High incidence of tuberculosis in patients treated for hepatitis C chronic infection
    Silvia Naomi de Oliveira Uehara, Christini Takemi Emori, Renata Mello Perez, Maria Cassia Jacintho Mendes-Correa, Adalgisa de Souza Paiva Ferreira, Ana Cristina de Castro Amaral Feldner, Antonio Eduardo Benedito Silva, Roberto José Carvalho Filho, Ivonete Sandra de Souza e Silva, Maria Lucia Cardoso Gomes Ferraz
    Brazilian Journal of Infectious Diseases, 2016
    Brazil is one of the 22 countries that concentrates 80% of global tuberculosis cases concomitantly to a large number of hepatitis C carriers and some epidemiological risk scenarios are coincident for both diseases. We analyzed tuberculosis cases that occurred during α-interferon-based therapy for hepatitis C in reference centers in Brazil between 2001 and 2012 and reviewed their medical records. Eighteen tuberculosis cases were observed in patients submitted to hepatitis C α-interferon-based therapy. All patients were human immunodeficiency virus-negative. Nine patients (50%) had extra-pulmonary tuberculosis; 15 (83%) showed significant liver fibrosis. Hepatitis C treatment was discontinued in 12 patients (67%) due to tuberculosis reactivation and six (33%) had sustained virological response. The majority of patients had a favorable outcome but one died. Considering the evidences of α-IFN interference over the containment of Mycobacterium tuberculosis, the immune impairment of cirrhotic patients, the increase of tuberculosis case reports during hepatitis C treatment with atypical and severe presentations and the negative impact on sustained virological response, we think these are strong arguments for latent tuberculosis infection screening before starting α-interferon-based therapy for any indication and even to consider IFN-free regimens against hepatitis C when a patient tests positive for latent tuberculosis infection.
  • Clinical and epidemiological profile of female blood donors with positive serology for viral hepatitis B
    Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Roberto José de Carvalho-Filho, Christine Takemi Emori, Fernando Akio Maryia, José Orlando Bordin, Antonio Eduardo Benedito Silva, Maria Lucia Gomes Ferraz
    Revista Da Sociedade Brasileira De Medicina Tropical, 2015
    INTRODUCTION Since women are frequently the minority among blood donors worldwide, studies evaluating this population usually reflect male features. We assessed the features of female blood donors with positive serology for HBV and compared them with those of men.METHODS The study comprised consecutive blood donors referred to a specialized liver disease center to be evaluated due to HBsAg- and/or anti-HBc-positive tests. RESULTS The study encompassed 1,273 individuals, 219 (17.2%) of whom were referred due to positive HBsAg test and 1,054 (82.8%) due to reactive anti-HBc test. Subjects' mean age was 36.8±10.9 years, and 28.7% were women. Female blood donors referred for positive HBsAg screening tests demonstrated higher prevalence of healthcare workers (9.3% vs 2.5%) and lower prevalence of sexual risk behaviors (15.1% vs 41.1%) and alcohol abuse (1.9% vs 19.8%) compared to men. Women had lower ALT (0.6 vs 0.8×ULN), AST (0.6 vs 0.8×ULN), direct bilirubin (0.2 vs 0.3mg/dL), and alkaline phosphatase (0.5 vs 0.6×ULN) levels and higher platelet count (223,380±50,293 vs 195,020±53,060/mm3). Women also had a higher prevalence of false-positive results (29.6% vs 17.0%). No differences were observed with respect to liver biopsies. Female blood donors referenced for reactive anti-HBc screening tests presented similar clinical, epidemiological, and biochemical characteristics to those reported for positive HBsAg screening tests and similarly had a higher prevalence of false-reactive results. CONCLUSIONS Compared to men, female blood donors with positive HBsAg and/or anti-HBc screening tests demonstrated higher prevalence of professional risk and false-positive results and reduced alteration of liver chemistry.
  • Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection
    Raul Carlos Wahle, Renata Mello Perez, Patrícia Fucuta Pereira, Elze Maria Gomes Oliveira, Christini Takemi Emori, Silvia Naomi de Oliveira Uehara, Ivonete Sandra de Souza Silva, Antônio Eduardo Benedito Silva, Maria Lucia Gomes Ferraz
    Brazilian Journal of Infectious Diseases, 2015
  • Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis?
    Raul Carlos Wahle, Renata de Mello Perez, Christini Takemi Emori, Silvia Naomi de Oliveira Uehara, Patrícia da Silva Fucuta, Cristina Melo Rocha, Ana Cristina de Castro Amaral Feldner, Ivonete Sandra de Souza e Silva, Roberto José Carvalho-Filho, Antônio Eduardo Benedito Silva, Maria Lucia Gomes Ferraz
    Annals of Hepatology, 2015
  • Do differences exist between chronic hepatitis C genotypes 2 and 3?
    Isaura Cunha Melo, Maria Lucia Gomes Ferraz, Renata Mello Perez, Christine Takemi Emori, Silvia Naomi de Oliveira Uehara, Roberto José de Carvalho-Filho, Antonio Eduardo Benedito Silva, Ivonete Sandra de Souza e Silva
    Revista Da Sociedade Brasileira De Medicina Tropical, 2014
  • Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients
    Christini Takemi Emori, Renata Melo Perez, Carla Adriana Loureiro de Matos, Silvia Naomi Oliveira Uehara, Patricia da Silva Fucuta Pereira, Ana Cristina Amaral Feldner, Roberto José de Carvalho-Filho, Ivonete Sandra de Souza e Silva, Antonio Eduardo Benedito Silva, Maria Lucia Gomes Ferraz
    Brazilian Journal of Infectious Diseases, 2014
  • Histological evolution of hepatitis C virus infection after renal transplantation
    Silvia Naomi de Oliveira Uehara, Christini Takemi Emori, Patrícia da Silva Fucuta Pereira, Renata M. Perez, José Osmar Medina Pestana, Valéria Pereira Lanzoni, Ivonete Sandra Souza e Silva, Antonio Eduardo Benedito Silva, Maria Lucia Cardoso Gomes Ferraz
    Clinical Transplantation, 2012
  • Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase
    Janaína Luz Narciso-Schiavon, Leonardo de Lucca Schiavon, Roberto José de Carvalho-Filho, Débora Yumi Hayashida, Jenny Hue Jiuan Wang, Tatiana Santana Souza, Christini Takemi Emori, Maria Lucia Gomes Ferraz, Antonio Eduardo Benedito Silva
    Sao Paulo Medical Journal, 2010
  • Chronic hepatitis C: Hepatic iron content does not correlate with response to antiviral therapy
    Patricia da Silva Fucuta Pereira, Ivonete Sandra de Souza e Silva, Silvia Naomi de Oliveira Uehara, Christini Takemi Emori, Valéria Pereira Lanzoni, Antonio Eduardo Benedito Silva, Maria Lucia Gomes Ferraz
    Revista do Instituto De Medicina Tropical De Sao Paulo, 2009

RECENT SCHOLAR PUBLICATIONS

  • High detection rate of parasitic load by qPCR targeting 18S rDNA in blood of patients with active leishmaniasis lesions
    GV Castanheira, VS Amato, FF Tuon, LR Dantas, SFG de Carvalho, ...
    European Journal of Clinical Microbiology & Infectious Diseases 44 (3), 717-728 , 2025
    2025
    Citations: 1
  • Early noninvasive evaluation of liver fibrosis after hepatitis c treatment: the impact of inflammation
    JB Xavier, J Schmillevitch, C Emori, S Uehara, EJ Nunes, ML Ferraz
    Arquivos de Gastroenterologia 61, e24043 , 2024
    2024
  • Avaliação precoce não invasiva da fibrose hepática após tratamento da hepatite c: o impacto da inflamação
    JB XAVIER, J SCHMILLEVITCH, C EMORI, S UEHARA, EJ NUNES, ...
    Arquivos de Gastroenterologia 61, e24043 , 2024
    2024
  • Cutaneous leishmaniasis in a rheumatoid arthritis patient receiving methotrexate.
    VS Amato, LAM Franco, GV Castanheira, RM de Souza, RCR Martins, ...
    2022
  • Hepatitis B Reactivation in HBsAg Negative Renal Transplant Patients with Evidence of Previous HBV Infection: A Not Neglectable Occurrence
    AP Leopercio, C Emori, EC Neiva, AL Silva Souza, AC Amaral, GA Vieira, ...
    OBM Transplantation 6 (4), 1-9 , 2022
    2022
  • Case report: cutaneous leishmaniasis in a rheumatoid arthritis patient receiving methotrexate
    VS Amato, RM de Souza, LAM Franco, RCR Martins, CAM da Silva, ...
    The American Journal of Tropical Medicine and Hygiene 107 (4), 785 , 2022
    2022
    Citations: 4
  • SARCOMA DE KAPOSI OCULAR COMO MANIFESTAÇÃO INICIAL DA SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA
    VSD de Oliveira, CT Emori, RC Mendes, EL de Lima, GT Calixto, ...
    The Brazilian Journal of Infectious Diseases 26, 102616 , 2022
    2022
  • P-25 SLOWER FIBROSIS PROGRESSION IN HEPATITIS C HEMOPHILIAC PATIENTS?
    DO Bastos, C Emori, SV Antunes, F Appel, ML Ferraz
    Annals of Hepatology 24, 100389 , 2021
    2021
  • Observational Study Evaluating the Outcome of Cirrhotic Hepatitis C Patients Submitted to Renal Transplantation
    CT Emori, SNO Uehara, AC Amaral, RJ Carvalho-Filho, SR Moreira, ...
    Transplantation Proceedings 52 (1), 89-96 , 2020
    2020
    Citations: 1
  • Changing pattern of chronic hepatitis C in renal transplant patients over 20 years
    CT Emori, SNO Uehara, RJ Carvalho-Filho, AC Amaral, ISS e Silva, ...
    European Journal of Gastroenterology & Hepatology 31 (9), 1141-1147 , 2019
    2019
    Citations: 4
  • Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients
    M Freitas-de Aguiar, AL Faria-Janes, GI Garcia-Brandes, C Takemi-Emori, ...
    Annals of Hepatology 18 (5), 685-692 , 2019
    2019
    Citations: 31
  • Evolução de pacientes cirróticos pelo vírus da Hepatite C submetidos a transplante renal
    CT Emori
    Universidade Federal de São Paulo (UNIFESP) , 2019
    2019
    Citations: 1
  • Prevalence of hepatitis delta virus among hemodialysis and renal transplant patients
    AMMA Pierre, ACCA Feldner, RJ Carvalho Filho, EPA Lopes, ...
    The International Journal of Artificial Organs 41 (3), 171-174 , 2018
    2018
    Citations: 1
  • Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection
    RCF Tavares, ACCA Feldner, JRR Pinho, SNO Uehara, CT Emori, ...
    European Journal of Gastroenterology & Hepatology 29 (7), 754-758 , 2017
    2017
  • High incidence of tuberculosis in patients treated for hepatitis C chronic infection
    SN de Oliveira Uehara, CT Emori, RM Perez, MCJ Mendes-Correa, ...
    The Brazilian Journal of Infectious Diseases 20 (2), 205-209 , 2016
    2016
    Citations: 30
  • Quantification of HBsAg in HBV Patients with Chronic Kidney Disease: Relationship with Viral Load and Histological Findings
    ASN Lima, CS Ferreira, IRD de Castro, JS Bernardino, R Alves, GA Silva, ...
    Journal of Hepatology 2 (64), S376 , 2016
    2016
  • Leishmaniasis reactivation during treatment of chronic hepatitis B with interferon alpha 2b-case report.
    CT Emori, SNO Uehara, RJ Carvalho Filho, IS Souza e Silva, ...
    2015
  • Reativação de leishmaniose durante tratamento de hepatite b crônica com alfainterferona 2b
    CT Emori, SN de Oliveira Uehara, RJ de Carvalho-Filho, IS de Souza, ...
    Revista de Patologia Tropical/Journal of Tropical Pathology 44 (3), 343-349 , 2015
    2015
  • Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis?
    RC Wahle, R de Mello Perez, CT Emori, SN de Oliveira Uehara, ...
    Annals of Hepatology 14 (3), 317-324 , 2015
    2015
    Citations: 7
  • Clinical and epidemiological profile of female blood donors with positive serology for viral hepatitis B
    JL Narciso-Schiavon, LL Schiavon, RJ Carvalho-Filho, CT Emori, ...
    Revista da Sociedade Brasileira de Medicina Tropical 48 (5), 524-531 , 2015
    2015
    Citations: 1

MOST CITED SCHOLAR PUBLICATIONS

  • Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients
    M Freitas-de Aguiar, AL Faria-Janes, GI Garcia-Brandes, C Takemi-Emori, ...
    Annals of Hepatology 18 (5), 685-692 , 2019
    2019
    Citations: 31
  • High incidence of tuberculosis in patients treated for hepatitis C chronic infection
    SN de Oliveira Uehara, CT Emori, RM Perez, MCJ Mendes-Correa, ...
    The Brazilian Journal of Infectious Diseases 20 (2), 205-209 , 2016
    2016
    Citations: 30
  • Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection
    RC Wahle, RM Perez, PF Pereira, EMG Oliveira, CT Emori, SNO Uehara, ...
    Brazilian Journal of Infectious Diseases 19, 533-537 , 2015
    2015
    Citations: 22
  • Histological evolution of hepatitis C virus infection after renal transplantation
    SN de Oliveira Uehara, CT Emori, PSF Pereira, RM Perez, JOM Pestana, ...
    Clinical transplantation 26 (6), 842-848 , 2012
    2012
    Citations: 19
  • Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients
    CT Emori, RM Perez, CAL Matos, SNO Uehara, PSF Pereira, ...
    Brazilian Journal of Infectious Diseases 18, 625-630 , 2014
    2014
    Citations: 14
  • Chronic hepatitis C: hepatic iron content does not correlate with response to antiviral therapy
    PSF Pereira, ISSE Silva, SNO Uehara, CT Emori, VP Lanzoni, AEB Silva, ...
    Revista do Instituto de Medicina Tropical de Sao Paulo 51 (6), 331-336 , 2009
    2009
    Citations: 12
  • Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase
    JL Narciso-Schiavon, LL Schiavon, RJ Carvalho-Filho, DY Hayashida, ...
    Sao Paulo Medical Journal 128 (6), 342-347 , 2010
    2010
    Citations: 10
  • Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis?
    RC Wahle, R de Mello Perez, CT Emori, SN de Oliveira Uehara, ...
    Annals of Hepatology 14 (3), 317-324 , 2015
    2015
    Citations: 7
  • Case report: cutaneous leishmaniasis in a rheumatoid arthritis patient receiving methotrexate
    VS Amato, RM de Souza, LAM Franco, RCR Martins, CAM da Silva, ...
    The American Journal of Tropical Medicine and Hygiene 107 (4), 785 , 2022
    2022
    Citations: 4
  • Changing pattern of chronic hepatitis C in renal transplant patients over 20 years
    CT Emori, SNO Uehara, RJ Carvalho-Filho, AC Amaral, ISS e Silva, ...
    European Journal of Gastroenterology & Hepatology 31 (9), 1141-1147 , 2019
    2019
    Citations: 4
  • Do differences exist between chronic hepatitis C genotypes 2 and 3?
    IC Melo, MLG Ferraz, RM Perez, CT Emori, SNO Uehara, ...
    Revista da Sociedade Brasileira de Medicina Tropical 47 (2), 143-148 , 2014
    2014
    Citations: 4
  • High detection rate of parasitic load by qPCR targeting 18S rDNA in blood of patients with active leishmaniasis lesions
    GV Castanheira, VS Amato, FF Tuon, LR Dantas, SFG de Carvalho, ...
    European Journal of Clinical Microbiology & Infectious Diseases 44 (3), 717-728 , 2025
    2025
    Citations: 1
  • Observational Study Evaluating the Outcome of Cirrhotic Hepatitis C Patients Submitted to Renal Transplantation
    CT Emori, SNO Uehara, AC Amaral, RJ Carvalho-Filho, SR Moreira, ...
    Transplantation Proceedings 52 (1), 89-96 , 2020
    2020
    Citations: 1
  • Evolução de pacientes cirróticos pelo vírus da Hepatite C submetidos a transplante renal
    CT Emori
    Universidade Federal de São Paulo (UNIFESP) , 2019
    2019
    Citations: 1
  • Prevalence of hepatitis delta virus among hemodialysis and renal transplant patients
    AMMA Pierre, ACCA Feldner, RJ Carvalho Filho, EPA Lopes, ...
    The International Journal of Artificial Organs 41 (3), 171-174 , 2018
    2018
    Citations: 1
  • Clinical and epidemiological profile of female blood donors with positive serology for viral hepatitis B
    JL Narciso-Schiavon, LL Schiavon, RJ Carvalho-Filho, CT Emori, ...
    Revista da Sociedade Brasileira de Medicina Tropical 48 (5), 524-531 , 2015
    2015
    Citations: 1
  • Treatment of Latent Tuberculosis in Patients with Hepatitis C and Advanced Fibrosis: 1542
    CT Emori, SN Uehara, ACA Feldner, AEB Silva, RJ Carvalho-Filho, I Silva, ...
    Hepatology 60, 940A , 2014
    2014
    Citations: 1
  • Early noninvasive evaluation of liver fibrosis after hepatitis c treatment: the impact of inflammation
    JB Xavier, J Schmillevitch, C Emori, S Uehara, EJ Nunes, ML Ferraz
    Arquivos de Gastroenterologia 61, e24043 , 2024
    2024
  • Avaliação precoce não invasiva da fibrose hepática após tratamento da hepatite c: o impacto da inflamação
    JB XAVIER, J SCHMILLEVITCH, C EMORI, S UEHARA, EJ NUNES, ...
    Arquivos de Gastroenterologia 61, e24043 , 2024
    2024
  • Cutaneous leishmaniasis in a rheumatoid arthritis patient receiving methotrexate.
    VS Amato, LAM Franco, GV Castanheira, RM de Souza, RCR Martins, ...
    2022